Related Experiment Videos
Autoimmune lymphoproliferative syndrome (ALPS).
1Arkansas Children's Hospital Research Institute, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA. bleesingjacobh@uams.edu
Current Pharmaceutical Design
|February 7, 2003
Summary
Autoimmune lymphoproliferative syndrome (ALPS) involves lymphocyte defects causing immune dysregulation, autoimmunity, and increased lymphoma risk. Further research into ALPS pathogenesis may illuminate general autoimmune disease mechanisms.
Area of Science:
- Immunology
- Molecular Biology
- Genetics
Background:
- Defective lymphocyte homeostasis characterizes Autoimmune Lymphoproliferative Syndrome (ALPS).
- This leads to lymphadenopathy, splenomegaly, autoimmunity, and heightened lymphoma risk.
- Unique laboratory findings reflect impaired Fas-mediated apoptosis and immune dysregulation.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying defective Fas-mediated apoptosis in ALPS.
- To investigate the complex genotype-phenotype relationships and disease penetrance.
- To explore additional factors contributing to ALPS pathogenesis, including immune regulation.
Main Methods:
- Analysis of molecular mechanisms of Fas-mediated apoptosis.
- Investigation of genotype-phenotype correlations.
- Evaluation of immune regulatory pathways, including IL-2/IL-2 receptor system and IL-10 levels.
Main Results:
- Understanding of defective Fas-mediated apoptosis and its link to ALPS pathogenesis has advanced.
- Family studies suggest additional genetic or environmental factors contribute to ALPS.
- Alterations in the IL-2/IL-2 receptor system and elevated IL-10 levels are implicated in immune dysregulation.
Conclusions:
- ALPS pathogenesis involves defective Fas-mediated apoptosis and potentially other immune regulatory defects.
- Further research is crucial for understanding ALPS incidence, natural history, and pathogenesis.
- Insights from ALPS may advance the understanding of autoimmune diseases broadly.